Mutational landscape of metastatic CRPC


Recently, MCTP investigators, in collaboration with the Prostate Cancer Foundation-Stand Up 2 Cancer (PCF-SU2C) International Dream Team Consortium, led the study to develop a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC) by obtaining a comprehensive landscape of cancer-related mutations in order to potentially incorporate this information for therapeutic strategies and/or enrolling subjects into appropriate clinical trials.  The study involved 8 clinical sites and two sequencing sites, and a total of 150 patient biospecimen were subject to comprehensive sequence analysis (whole-exome and transcriptome). Overall, the sequencing results revealed that 90% of mCRPC samples harbored clinically actionable molecular alterations in several major pathways: AR, PI3K, WNT, DNA repair, and cell cycle. The results of this study was recently published in Cell (Cell. 2015 May 21;161(5):1215-28).

Read more.